Skip to Content

Curaleaf Holdings Inc

CURA: XTSE (CAN)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
CAD 71.90VbvsHybqhjn

Curaleaf Earnings: Top-Line Growth Remains Sluggish, but Long-Term Potential Remains

No-moat Curaleaf’s third-quarter results reflected continued weakness in the top line, with net revenue up just 1% sequentially, and adjusted EBITDA margin remained low at 21% compared with 26% a year ago. We’re likely to trim our $17/CAD 23 fair value estimate by a few dollars to reflect the stubborn top-line weakness.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CURA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center